生命科学资讯

What 3 recent FDA rejections reveal about shifts inside the agency

Inside the race to thwart the dramatic rise in early-onset colorectal cancer

J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks

Big Pharma’s next entrant could come from China

How PBM reforms could push drugmakers into the pricing spotlight

Biohaven says FDA roadblocks leave rare disease patients in limbo

China’s biopharma advance draws financial investment

Will the FDA yank mRNA vaccines?

How does the FDA really feel about psychedelics? We could soon find out.

Operating a new standard for life-saving pharmaceutical logistics

No one-trick pony in oncology, Merck’s cancer footprint is expanding

Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.

Pharma could be on the cusp of finally breaking the blood-brain barrier

AI is slashing jobs across industries. Will pharma be next?

More drugmakers are turning to cancer combos. Will it help patients live longer?

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief

Ovid takes another big swing in neuroscience under a new CEO

Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift

A protein model designed for space could expand pharma’s definition of ‘druggability’

New FDA guidance that’s a ‘huge deal’ for clinical trials